GHK-Cu 50mg Dosage Protocol

Dosing & Reconstitution

Reconstitution

Recommended BAC water: 2 mL → 50 mg ÷ 2 mL = 25 mg/mL

1. Swab the rubber stoppers on the GHK-Cu vial and BAC vial. Let dry.
2. Draw 2 mL bacteriostatic water (1 mL at a time if using a 1 mL syringe).
3. Inject slowly down the inside wall of the peptide vial. Do not shoot directly onto the powder.
4. Swirl gently until clear. Do not shake.
5. Label with date and BAC volume. Refrigerate immediately.

With BAC, expect roughly 25–30 days stability refrigerated. See the Storage Guide.

Injectable dosing

Subcutaneous injection is the common research route for systemic and skin-from-within effects.

Level	Daily dose	Volume (25 mg/mL)	U-100 units	Days per vial
Low	2.5 mg	0.10 mL	10 units	20
Medium	5 mg	0.20 mL	20 units	10
High	7.5 mg	0.30 mL	30 units	6–7
High	10 mg	0.40 mL	40 units	5

Formula: dose volume = desired mg ÷ 25. Syringe units = dose volume × 100.

Example: 5 mg → 5 ÷ 25 = 0.20 mL → 20 units on a U-100 syringe.

Inject subcutaneously (belly, thigh, or upper arm). Rotate sites. Fresh needle each time; do not reuse.

Cycle

Suggested schedule (anecdotal): 8–12 weeks on, then 4 weeks off.

Topical cosmetic trials often run 12 weeks before results are assessed, which aligns with common community cycles for skin-focused goals. Shorter runs may still show early changes; longer continuous use without breaks has less formal data for injectable routes.

Phase	Duration	Notes
On	8–12 weeks	Daily injectable and/or 1–2× daily topical
Off	4 weeks	No peptide; maintain baseline skincare if desired

At 5 mg/day injectable, one 50 mg vial lasts about 10 days. Plan vial count for the full on-phase before you start.

Alternative Protocols

Topical moisturiser mix

Reconstitute as above, then blend the liquid into a plain, fragrance-free moisturiser. Apply to target areas 1–2× daily. This mirrors how much of the human research was done (cream/serum delivery). Full mixing steps: Deployment Methods · Topical.

Serum and soap (anecdotal)

Dedicated GHK-Cu face serum for facial skin and GHK-Cu soap or body products for larger areas. Apply 1–2× daily where you want effects.

Microneedling (anecdotal)

Some users microneedle 1–2× per week (or as tolerated) before topical application. Pen-style devices are generally preferred over stamps or rollers. Sterility matters when skin is broken.

Injectable + topical together (anecdotal)

Common approach: injectable for inside-out effects, topical for local skin. Community reports treat these as complementary.

Pre-mixed blends

GHK-Cu ships in research blends such as GLOW (GHK-Cu + BPC-157 + TB-500) and KLOW (GHK-Cu + BPC-157 + KPV + TB-500). Fixed ratios; you cannot adjust individual peptide amounts after mixing. See Blends.

Multi-vial stacks

For separate control over dose and timing, run GHK-Cu alongside other vials on a coordinated schedule. See Stacks (e.g. Full Skin, Hair Restoration).

AHK-Cu

AHK-Cu (alanine-histidine-lysine copper) is a related copper peptide often discussed for hair. Results vary; some users try both and keep whichever works better. Head-to-head clinical data vs GHK-Cu are limited.

Supplementary Things to Consider

Combinations (anecdotal)

• Anti-aging / skin: Epithalon, glutathione, MOTS-c, NAD+, SS-31, Humanin, methylene blue
• Hair: minoxidil, finasteride, dutasteride, ketoconazole, RU-58841, topical androgen modulators
• Skin support: HGH (separate legal and safety profile)

Every added compound brings interaction risk. Add one thing at a time when possible.

Zinc balance (anecdotal)

Copper and zinc compete for absorption. A rough community guideline is about 1:10 copper to zinc in overall intake. Some users supplement zinc when running higher GHK-Cu doses.

Copper toxicity

Even 10 mg GHK-Cu injectable delivers roughly 1–2 mg elemental copper, far below acute toxic thresholds in published copper tox data (ATSDR Copper ToxProfile). More is not better. Stay within common dose bands.

Side effects

Injectable: injection-site redness, mild irritation.
Topical: occasional irritation or breakouts in sensitive skin.
Stop if reactions persist. Injectable route has less formal safety data than topical cosmetics.

Supplies

• GHK-Cu 50 mg lyophilized vial
• Bacteriostatic water (BAC), 10 mL or 30 mL vial
• U-100 insulin syringes, 1 mL, 29G–31G × ½″
• Alcohol swabs
• Sharps container
• Refrigerator space for reconstituted vial
• Optional (topical): plain fragrance-free moisturiser, serum, or soap base
• Optional (topical): microneedling pen if using that protocol

What Is GHK-Cu

GHK-Cu (glycyl-L-histidyl-L-lysine copper) is a naturally occurring tripeptide that binds copper(II). Loren Pickart isolated it from human plasma in 1973; levels decline with age. The copper supports lysyl oxidase and other enzymes involved in collagen and elastin cross-linking.

Research focus: dermal remodeling, fibroblast activity, collagen I/III, elastin, glycosaminoglycans, and MMP/TIMP balance. Injectable human data are thinner than topical cosmetic trials, but reconstitution follows standard lyophilized peptide practice.

Research

Collagen and wound repair

Rat wound-chamber models: GHK-Cu increased dry weight, DNA, protein, collagen, and GAGs in a dose-dependent way. Type I and III collagen mRNAs rose (Maquart et al., 1993). Fibroblast cultures showed direct collagen stimulation (Maquart et al., 1988).

Skin aging and topical use

Human topical work over 8–12 weeks reports improved density, firmness, laxity, and wrinkle appearance. Thigh study: 70% collagen increase with GHK-Cu vs 50% (vitamin C) and 40% (retinoic acid) (Abdulghani et al., 1998). Facial cream data in photoaged skin over 12 weeks (Pickart & Margolina, 2018, citing Leyden et al., 2002). Randomized split-face trial: reduced wrinkle volume and depth (Canfield et al., 2017).

Gene regulation

Reviews describe GHK shifting large gene sets toward repair and away from inflammatory patterns (Pickart et al., 2015; Pickart & Margolina, 2018).

References

1. Maquart FX, Pickart L, et al. In vivo stimulation of connective tissue accumulation by GHK-Cu in rat wounds. J Clin Invest. 1993. PMID 8227353
2. Maquart FX, Pickart L, et al. Stimulation of collagen synthesis in fibroblast cultures by GHK-Cu. FEBS Lett. 1988. PMID 3192171
3. Abdulghani AA, et al. Topical creams containing vitamin C, copper-binding peptide, and melatonin vs tretinoin. Disease Management and Clinical Outcomes. 1998. DOI 10.1016/S1088-3371(98)00011-4
4. Canfield D, et al. GHK-Cu effects on MMP/TIMP, collagen, elastin, and facial wrinkle parameters. J Cosmet Dermatol Sci Appl. 2017. DOI 10.4172/2329-8847.1000166
5. Pickart L, et al. GHK peptide as a natural modulator of multiple pathways in skin regeneration. Biomed Res Int. 2015. PMID 26236730
6. Pickart L, Margolina A. Regenerative and protective actions of GHK-Cu in light of new gene data. Int J Mol Sci. 2018. PMID 29986520
7. ATSDR. Toxicological Profile for Copper. U.S. Department of Health and Human Services. PDF

Leyden JJ, et al. Twelve-week topical GHK-Cu facial cream results in photoaged skin. American Academy of Dermatology 60th Annual Meeting, 2002. Conference proceedings; summarized in reference 6 above.